Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection
This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce.
📰 Original Source
Read full article at Fool →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.